• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Biolase Inc.

    9/12/23 3:26:29 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care
    Get the next $BIOL alert in real time by email
    SC 13G 1 ek_sc13g.htm FORM 13-G Form 13-G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. ___)*

    Biolase, Inc.

    (Name of Issuer)

    Common Stock, $.0001 par value per share

    (Title of Class of Securities)

    0911702

    (CUSIP Number)

    9/11/2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [_]  Rule 13d-1(b) 

     

    [x]  Rule 13d-1(c) 

     

    [_]  Rule 13d-1(d) 

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    SCHEDULE 13G

    CUSIP No.

    0911702

     

    1

    Names of Reporting Persons

    Edson Krefta

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  [ ]
    (b)  [   ]

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

    United States

    Number of Shares Beneficially Owned by Each Reporting Person With:

     

    5

    Sole Voting Power

    71,000

    6

    Shared Voting Power

     

    7

    Sole Dispositive Power

    71,000

    8

    Shared Dispositive Power

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

    71,000

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    [  ]

    11

    Percent of class represented by amount in row (9)

    6.8%

    12

    Type of Reporting Person (See Instructions)

    IN


    Page 2 of 5


     

    Item 1.

    (a)Name of Issuer:  

         Biolase, Inc. (the issuer”)

    (b)Address of Issuer’s Principal Executive Offices:  

    27042 Towne Centre Drive, Suite 270, Foothill Ranch, CA 92610

    Item 2.

    (a)Name of Person Filing:  

    Edson Krefta

    (b)Address of Principal Business Office or, if None, Residence:  

    10 Winterberry Lane, Tewksbury MA 01876

    (c)Citizenship:  

    United States

    (d)Title and Class of Securities:  

    Common Stock, par value $0.0001 per share (“Common Stock”).

    (e)CUSIP No.:  

    0911702

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: 

    (a)[_]Broker or dealer registered under Section 15 of the Act; 

    (b)[_]Bank as defined in Section 3(a)(6) of the Act; 

    (c)[_]Insurance company as defined in Section 3(a)(19) of the Act; 

    (d)[_]Investment company registered under Section 8 of the Investment Company Act of 1940; 

    (e)[_]An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); 

    (f)[_]An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); 

    (g)[_]A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); 

    (h)[_]A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

    (i)[_]A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; 


    Page 3 of 5


    (j)[_]A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); 

    (k)[_]Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ 

    Item 4.Ownership 

    (a)Amount Beneficially Owned:  

    71,000 common shares  

    (b)Percent of Class:  

    6.8%

    (c)Number of shares as to which such person has: 

    (i)Sole power to vote or to direct the vote:  

    71,000 

    (ii)Shared power to vote or to direct the vote: 

    (iii)Sole power to dispose or to direct the disposition of:  

    71,000

    (iv)Shared power to dispose or to direct the disposition of: 

    Item 5.Ownership of Five Percent or Less of a Class.  

    Not Applicable. 

    Item 6.Ownership of more than Five Percent on Behalf of Another Person.  

    Not Applicable.

    Item 7.Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.  

    Not applicable

    Item 8.Identification and classification of members of the group. 

    Not Applicable.

    Item 9.Notice of Dissolution of Group. 

    Not Applicable.

    Item 10.Certifications. 


    Page 4 of 5


    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect other then solely in connection with a nomination under 240.14a-11.


    Page 5 of 5


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  9/11/2023

    /s/ Edson Krefta – Individual Investor

    Name/Title

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).


    Page 6 of 5

    Get the next $BIOL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BIOLASE Voluntarily Initiates Chapter 11 Proceedings

      LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.The Company also announced today that it is pursuing a sale process under Section 363 of the Bankruptcy Code in conjunction with the filing. To this end, BIOL

      10/1/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

      LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

      8/8/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BIOL
    Leadership Updates

    Live Leadership Updates

    See more
    • Strateos Appoints Alexander K. Arrow as Chief Financial Officer and Expands Team

      Juliet M. Moritz appointed Vice President, Project Management Office Strateos, Inc., a pioneer in the development of remote access laboratories and lab automation software for life science research, today announced the appointment of Alexander K. Arrow, MD, CFA, as Chief Financial Officer. Dr. Arrow will join the Executive Leadership team and play a key role in leading the company's business and finance strategy focused on growth and new investments. The company has also named Juliet M. Moritz, MPH, Vice President, Project Management Office, reflecting the significant demand by large pharmaceutical companies and contract research organizations for deployment of Strateos Lodestar™ Software.

      2/8/23 8:00:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICER

      Dr. Morrow brings extensive clinical, dental and DSO experience to help expand laser adoption globally LAKE FOREST, Calif., Oct. 13, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced the appointment of Russell Morrow, D.D.S. as Chief Dental Officer ("CDO"), effective November 1, 2022. Dr. Samuel Low, who has served as Chief Dental Officer since 2016, will be taking on a new role as Vice President, Clinical Strategic Alliances, where he will focus on building partnerships and growth with Dental Service Organizations (DSOs), universities and government institutions.

      10/13/22 6:30:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE Expands Core Capabilities As It Appoints Three New Board Members With Significant Dental Experience

      FOOTHILL RANCH, Calif., Aug. 16, 2021 /PRNewswire/ -- Demonstrating a deep commitment to expanding the core capabilities and diversity of its Board of Directors, BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced it has appointed three new board members to its Board of Directors (the "Board"), effective immediately. Drs. Kathleen T. O'Loughlin, Carol Gomez Summerhays, and Martha Somerman join a Board that has been instrumental in establishing and implementing the Company's business plan, which has demonstrated significant growth over the past several quarters.

      8/16/21 6:30:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/23/24 4:05:29 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/21/24 4:39:54 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/14/24 4:06:57 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    SEC Filings

    See more
    • SEC Form 8-K filed by Biolase Inc.

      8-K - BIOLASE, INC (0000811240) (Filer)

      10/8/24 4:47:14 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • Biolase Inc. filed SEC Form 8-K: Bankruptcy or Receivership

      8-K - BIOLASE, INC (0000811240) (Filer)

      10/1/24 4:05:10 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Biolase Inc.

      8-K - BIOLASE, INC (0000811240) (Filer)

      9/6/24 4:05:08 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Financials

    Live finance-specific insights

    See more
    • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

      LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

      8/8/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability

      Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and SuccessLAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024.First Quarter Financial HighlightsGenerated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialistsThird strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptionsGross margin was re

      5/13/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Colliers Securities resumed coverage on BIOLASE with a new price target

      Colliers Securities resumed coverage of BIOLASE with a rating of Buy and set a new price target of $1.15

      3/8/21 4:09:02 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • Maxim Group reiterated coverage on BIOLASE with a new price target

      Maxim Group reiterated coverage of BIOLASE with a rating of Buy and set a new price target of $2.00 from $1.00 previously

      1/26/21 4:24:15 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Yale Kenneth P.

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:10:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Somerman Martha J. Dds, Phd

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:08:49 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Roper Jess

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:07:19 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care